Hansa Grows Cash Pile Ahead of Idefirix US Filing
European Launches Progressing Smoothly
Executive Summary
The Swedish biotech has added another $40m to its coffers as it advances its potential ‘pipeline in a product’ for kidney disease.
You may also be interested in...
Finance Watch: Stark Contrast As Big FOPOs Reach Market, Other Firms Cut Costs
Public Company Edition: Arvinas grossed $350m in a private placement, while Xenon brought in $345m and Pharvaris raised $300m in follow-on public offerings. Fundraising remains challenging, however, so IGM Biosciences, Hansa Biopharma and other companies cut costs to save money.
A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA
The FDA and Sarepta have had a controversial history with the accelerated approvals of the firm’s earlier drugs for Duchenne muscular dystrophy – but the company’s investigational gene therapy, SRP-9001, now under a priority review, could be a genuine breakthrough.
Hansa Biopharma To Be Transformed By Idefirix Approval In EU
With the first approval in the bag for its lead product, Idefirix, from the European Commission, Sweden’s Hansa Biopharma is planning to launch the product in Europe using its own medical and commercial organization in core markets.